Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis.

Da-Chuan FAN; Xiang-Dong WANG; Cheng-Shuo WANG; Yang WANG; Fei-Fei CAO; Luo ZHANG

Return

Suppression of Immunotherapy on Group 2 Innate Lymphoid Cells in Allergic Rhinitis.

Author: Da-Chuan FAN ¹ ; Xiang-Dong WANG ² ; Cheng-Shuo WANG ³ ; Yang WANG ² ; Fei-Fei CAO ³ ; Luo ZHANG ³ ;
Author Information

1. Department of Otolaryngology Head and Neck Surgery; Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730; Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150001, China.
2. Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China.
3. Department of Otolaryngology Head and Neck Surgery
Publication Type:Journal Article
MeSH: Adolescent; Adult; Animals; Dermatophagoides pteronyssinus; immunology; Female; Flow Cytometry; Humans; Interleukin-13; metabolism; Interleukin-5; metabolism; Lymphocytes; immunology; metabolism; Male; Rhinitis, Allergic; immunology; metabolism; therapy; Skin Tests; Sublingual Immunotherapy; Young Adult
From: Chinese Medical Journal 2016;129(23):2824-2828
CountryChina
Language:English
Abstract:
BACKGROUNDGroup 2 innate lymphoid cells (ILC2s) are regarded as a novel population of lineage-negative cells that induce innate Type 2 responses by producing the critical Th2-type cytokines interleukin (IL)-5 and IL-13. ILC2s as key players in the development of allergic rhinitis (AR) have been proved, however, the effect of subcutaneous immunotherapy (SCIT) with dermatophagoides pteronyssinus extract (Der p-SCIT) on ILC2s in AR patients is not clear. This study aimed to investigate the response of ILC2s of peripheral blood in house dust mites (HDM)-sensitized Chinese patients with AR who received SCIT with Der P extract.
METHODSSeven healthy controls without symptoms of AR who had negative reactions to any of the allergens from skin-prick testing, nine patients diagnosed with persistent AR according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, and 24 AR patients who received Der p-SCIT for 1.0-3.5 years were recruited for the study. ILC2s in the peripheral blood were evaluated using flow cytometry. The severity of their symptoms of all participants was rated based on the Total 5 symptom score.
RESULTSAmong 40 participants, 9 AR patients were assigned to the untreated group, 24 AR patients receiving Der p-SCIT were assigned to the immunotherapy group, and 7 healthy controls without symptoms of AR were assigned to healthy control group. The mean Total 5 symptom score of immunotherapy group was significantly lower than that of untreated group (4.3 ± 1.4 vs. 10.1 ± 2.5, P< 0.001). Similarly, the levels of ILC2s in the peripheral blood of immunotherapy group were significantly reduced compared with that in untreated group (P < 0.001), but were not significantly different from healthy controls (P = 0.775). Further subgroup analysis based on the duration of SCIT therapy (1.0-2.0 years [SCIT1-2], 2.0-3.0 years [SCIT2-3], and 3.0-3.5 years [SCIT3-3.5]) showed that the percentage of ILC2s was not significantly different between SCIT1-2, SCIT2-3, and SCIT3-3.5groups (SCIT1-2 vs. SCIT2-3: P = 0.268; SCIT1-2vs. SCIT3-3.5: P = 0.635; and SCIT2-3 vs. SCIT3-3.5: P = 0.787).
CONCLUSIONSThe present study highlighted the suppression of Der p-SCIT on ILC2s in HDM-AR patients. ILC2s identified in peripheral blood can be used as an effective biomarker for Der p-SCIT.